© 2022 MJH Life Sciences and AJMC. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Examining current treatment options for brain metastases in metastatic HER2+ breast cancer and assessing the clinical and economic burden.
January 14th 2021
Sarah Sammons, MD, provides an overview of the progression HER2-positive metastatic breast cancer [mBC] and common areas for the development of metastases, including in the brain.
Insights on diagnosing patients who have HER2+ metastatic breast cancer with brain metastases based on current NCCN Guidelines recommendations when they may present with them during the course of treatment, and the impact on quality of life.
Kevin M. Kalinsky, MD, MS, discusses monitoring patients with HER2-positive mBC who have asymptomatic brain metastases and advancements in therapy for HER2-positive disease leading to increased brain metastases.
Sarah Sammons, MD, and Bhavesh Shah, RPh, BCOP, discuss the increase in health care resource utilization associated with brain metastases for HER2-positive mBC.
Exploring current advances in treatment options beyond the second-line setting for progressive HER2-positive metastatic breast cancer.
The goals of therapy and unmet needs for patients with HER2-positive metastatic breast cancer at risk for brain metastases are examined.
A review of the HER2CLIMB study using oral the TKI tucatinib as therapy for HER2-positive metastatic breast cancer.
Sarah Sammons, MD, and Kevin M. Kalinsky, MD, MS, review the phase 2 LANDSCAPE trial using lapatinib for patients with HER2+ mBC and a history of brain metastases.
A review of the NALA study looking at the use of capecitabine plus neratinib in patients with pretreated metastatic HER2-positive breast cancer.
Kevin M. Kalinsky, MD, MS, and Sarah Sammons, MD, review the phase 2 single-arm trial DESTINY-Breast01, exploring the use of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer.